Case Report

Multiple endocrine neoplasia type 1 (MEN1) presenting with renal stones: Case report and review

Mohamed N. Ibrahim, MD*, James Liem, MD, Ahmed ElKady, MD

Department of Diagnostic Radiology, Rotherham General Hospital, Moorgate Road, Rotherham, South Yorkshire S60 2UG, United Kingdom

ARTICLE INFO

Article history:
Received 24 August 2020
Revised 16 September 2020
Accepted 20 September 2020

Keywords:
Multiple endocrine neoplasia type 1
Renal stones
Prolactinoima
Parathyroid adenoma
Pancreatic neuroendocrine tumors

ABSTRACT

Multiple endocrine neoplasia type 1 (MEN1) is a complex, autosomal dominant inherited syndrome characterized by 3 different tumors (parathyroid, anterior pituitary, and pancreatic islet). The diagnosis is defined clinically by the presence of 2 or more primary tumors. We report the case of a 35 years old patient who presented with recurrent renal stones and imaging findings for MEN1. Computed tomography pancreas revealed a mass in the tail which was confirmed by magnetic resonance imaging. Ultrasound of her neck showed a mass on the left side and MIBI scan diagnosed a parathyroid adenoma which was later pathologically confirmed.

© 2020 The Authors. Published by Elsevier Inc. on behalf of University of Washington. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Introduction

Multiple endocrine neoplasia type 1 (MEN1) is a complex, autosomal dominant inherited syndrome caused by mutations in the MEN1 tumor suppressor gene. The diagnosis is defined clinically by the presence of at least 2 primary MEN1 tumors (parathyroid, anterior pituitary, and pancreatic islet). We described a case of MEN 1 who presented with 3 types of tumors showing classic imaging studies. Written consent from the patient was taken and approval of the research office of the hospital.

Case report

A 35-year-old female presented to the Urgent and Emergency care center with left flank pain and vomiting. The urine dipstick was negative. Her past medical history included a prolactinoima for about 12 years and recurrent renal stones for a few years. She has a family history of parathyroid diseases and unknown abdominal tumors. She was on 500 mcg cabergoline once per week to treat hyperprolactinemia with the previous noncompliance to medication.

Her blood tests were – Calcium: 3.48 mmol (2.1-2.6), Phosphate: 0.6 mmol (0.8-1.5) Parathyroid: 54.37 pmol/L (1.95-8.49). Her kidney function tests and eGFR were normal.

* Corresponding author.
E-mail address: mohamednabil2005@gmail.com (M.N. Ibrahim).
https://doi.org/10.1016/j.radcr.2020.09.037
Vitamin D level was 30 nmol/L (<25 nmol/L) and the Prolactin level was 3341 mIU (0-646). TSH was normal. Computed tomography KUB was requested shortly in urgent and emergency care center (Fig. 1).

The patient was admitted to the hospital under the medical team to treat her hypercalcemia. Two days after admission a CT pancreas was performed (Fig. 2).

An magnetic resonance imaging Pancreas 3 days later confirmed the findings (Fig. 3).

She had a previous magnetic resonance imaging pituitary gland 6 years ago (Fig. 4).

Two weeks after admission a neck ultrasound followed by a MIBI scan was requested (Figs. 5 and 6).

Our patient had a history of a pituitary prolactinoma and newly discovered pancreatic and parathyroid tumors, meeting the clinical criteria for the diagnosis of MEN. Her young age at presentation and family history of parathyroid disease suggest familial MEN1.

Parathyroidectomy was done after 1 month and histopathology confirmed the parathyroid adenomatous tissue with some atypical features but no evidence of invasive neoplasia.

Afterward, she had developed a new episode of renal stone disease and hydronephrosis after which a nephrostomy tube was inserted.

**Discussion**

MEN1 syndrome is most commonly inherited as an autosomal dominant condition (90%) but can occur sporadically, with an incidence of 0.25% from random postmortem studies [2,3].

The diagnosis of MEN1 can be made clinically based on family history, or directly with genetic testing for a MEN1 mutation [2]. The clinical diagnosis of MEN1 includes the presence of 2 or more primary endocrine tumors associated with MEN1 (parathyroid adenomas, enteropancreatic tumors, and pituitary adenomas) [2,4]. The diagnosis based on family history requires only 1 of the associated primary endocrine tumors in someone who has a first-degree relative with diagnosed MEN1 (Table 1) [2].

Parathyroid adenomas are the most frequently occurring tumor in patients with MEN1, occurring in 90% of patients by age 40 [3,5]. These tumors can cause primary hyperparathyroidism and patients may present with hypercalcemia, nephrolithiasis, and osteitis fibrosa cystica [2,4,6]. The age at symptoms onset of parathyroid adenoma is earlier in patients with MEN1 compared to those without and typically occurring at approximately 20-25 years of age compared to 55 years of age, respectively [2].

Furthermore, it is estimated that 1%-18% of patients diagnosed with primary hyperparathyroidism will have MEN1. The degree of hypercalcemia in these individuals is usually mild and patients may be asymptomatic or present with polydipsia, polyuria, constipation, malaise, altered mentation, hypertension, shortened QT interval, peptic ulcer disease, urolithiasis, and/or decreased bone mineral density with increased fracture risk. There is a high prevalence of urolithiasis and early bone mineral loss in young individuals with MEN1-associated primary hyperparathyroidism, and bone or renal complications are progressively more frequent, extensive and severe in long-standing primary hyperparathyroidism cases and those associated with gastrinoma [7,8].

---

**Fig. 1 – Noncontrast CT KUB showing bilateral small renal stones (white arrows). No hydronephrosis.**
Fig. 2 – (A) Pre-contrast CT pancreas: showing a solid isodense mass compared to the pancreatic parenchyma in the tail of the pancreas measuring 2.5 x 2.1 cm (red arrow). (B) Postcontrast arterial phase: the mass demonstrates Iso to mild high attenuation compared to the pancreatic parenchyma (yellow arrow) (C) Venous phase: the lesion is also seen as a well-circumscribed hyperdense mass (white arrow). (Color version of figure is available online.)

Fig. 3 – (A) MRI pancreas axial T2 WIs: confirms the mass in the pancreatic tail appearing iso-intense compared to the pancreatic parenchyma (white arrow) (B) Axial T1 WIs precontrast: the mass appearing hypointense compared to the rest of the pancreas (yellow arrow). (C) Postcontrast arterial phase: enhancement similar to pancreatic parenchyma (black arrow). (D) MRI pancreas DWIs (B value 400): the mass shows mild diffusion restriction (blue arrow). (E) ADC map: shows a relative signal loss (red arrow). (Color version of figure is available online.)
Fig. 4 – (A) MRI pituitary gland coronal T1WIs: reveals deviation of the pituitary stalk to the left side (yellow arrow) (B) Coronal T2WIs: shows a small mass of isointense signal to the grey matter in the right aspect of the pituitary gland measuring 7 mm (red arrow), the appearance is consistent with a microadenoma. (Color version of figure is available online.)

Fig. 5 – (A) Transverse greyscale U/S image of the neck: shows a hypoechoic nodule compared to the thyroid parenchyma in the left side of the neck measuring 3.3 x 2.2 cm (black arrow) with a normal appearance of the left thyroid lobe (white arrow) (B) Longitudinal greyscale image: the nodule lying close to the inferior aspect of the left thyroid lobe (white arrows) with anechoic central areas representing cystic changes (black arrow) (C) Doppler mode image of the neck: the nodule showing increased vascularity.
Our patient presented in her mid-thirties but she had previously experienced 2 episodes of nephrolithiasis during her late twenties with calcium-rich stones. During workup, the patient’s serum calcium and parathyroid hormone levels were both elevated.

Evaluation for patients with hyperparathyroidism typically includes an ultrasound scan as an initial screening for underlying parathyroid adenoma followed by nuclear technetium Tc-99m sestamibi scintigraphy for confirmation. Sestamibi scintigraphy has a sensitivity and specificity of >90% for lesions that demonstrate retention of sestamibi radiotracer on delayed imaging [9].

Management of parathyroid adenomas is typically surgical, with the removal of the overactive glands with either a subtotal or total parathyroidectomy; however, noting that patients with MEN1 have an increased risk of persistent or recurrent hypercalcemia after subtotal surgery, which is thought to be secondary to their tendency toward multiglandular disease, is important [2,10].

In our case, one parathyroid adenoma was identified by initial ultrasound screening and confirmed with sestamibi scintigraphy.

Biochemical screening for primary hyperparathyroidism in patients with MEN1 should be performed annually with an assessment of serum calcium and parathyroid hormone levels [2].

Pancreatic neuroendocrine tumors (pNETs) are estimated to occur in 30%-80% of patients with MEN1, and up to 80%-100% of patients in postmortem studies. MEN1 is the most common hereditary syndrome associated with pNETs with approximately 10% of all pNETs being associated with MEN1 [11].

Although not the most common tumors, malignant enteropancreatic neuroendocrine tumors are the leading cause
of mortality in patients with MEN1 [5]. Associated tu-
mors of the pancreatic islet cells can be either function-
ing (hormone-secreting) or nonfunctioning (non-hormone-
secreting). Hormone-secreting tumors include gastrinomas
(40% incidence), insulinomas (10% incidence), and vipomas
and glucagonomas (2% incidence) [3].

Gastrinomas, the most commonly occurring enteropancre-
atic tumor in patients with MEN1, are often multiple, with
metastases identified in approximately 50% of these patients
at the time of diagnosis [3]. Malignant gastrinomas account
for the majority of neuroendocrine tumor-related MEN1 deaths
[5]. Clinically, gastrinomas cause gastric acid hypersecretion
and recurrent peptic ulcers with diarrhea, known as Zollinger-
Ellison syndrome [12,13]. Nonfunctioning pNETs are among
the most common enteropancreatic tumors in MEN1 [14].

Our patient did not have symptoms or laboratory findings
to suggest that the pancreatic tail tumor is hormonally func-
tioning.

Pituitary tumors may occur in up to 60% of patients with
MEN1, although the frequency reported in the literature is
variable [3] Prolactinomas are the most commonly occurring
pituitary tumors in patients with MEN1, with a prevalence of
20% by age 40 [3].

Patients with pituitary tumors can present with headaches
and visual field deficits because of tumor size and growth.
Prolactinomas in particular can cause erectile dysfunction
and decreased libido in men or amenorrhea and galactor-
rea in women resulting from increased prolactin [2]. The
management of prolactinomas typically involves transphe-
noidal resection of the tumor or medical management with
bromocriptine or cabergoline therapy. MEN1-associated pitu-
itary tumors, however, tend to be more aggressive and resis-
tant to therapy and surgery than sporadic pituitary tumors [2].

In our case, the patient had a history of galactorrhea which
was treated with cabergoline and was under regular follow-
up of her prolactin from 6 years before the diagnosis of MEN
syndrome.

Conclusion

Diagnosis of MEN1 depends on having a high level of suspicion
in patients who present with features of hyperparathyroidism,
prolactinoma, or increased gastric acid secretion. Our patient
presents a classic example of MEN1 syndrome with tu-
mors in all 3 defining endocrine organs, including pituitary
prolactinoma, parathyroid adenoma, and pancreatic neuroen-
docrine tumor (nonfunctioning). When the clinical suspicion
for MEN1 is high, endocrinology evaluation with appropriate
laboratory workup and imaging evaluation as described for
this patient is advised then follow-up and genetic counseling.

Patient Consent

Written consent from the patient was taken.

REFERENCES

[1] Chandrasekharappa SC, Guru SC, Manickam P, Olufemi SE, Collins FS, Emmert-Buck MR, et al. Positional cloning of the
gene for multiple endocrine neoplasia-type 1. Science. 1997;276:404–7 [PubMed] [CrossRef] [Google Scholar].
doi:10.1126/science.276.5311.404.

[2] Thakker RV, Newey PJ, Walls GV, et al. Endocrine Society. Clinical practice guidelines for multiple endocrine neoplasia
type 1 (MEN1). J Clin Endocrinol Metab 2012;97(9):2990–3011 [PubMed] [CrossRef] [Google Scholar].
doi:10.1210/jc.2012-1230.

[3] Almeida MQ, Stratakis CA. Solid tumors associated with multiple endocrine neoplasias. Cancer Genet Cytogenet
2010;203(1):30–6 [PMC free article] [PubMed] [CrossRef] [Google Scholar]. doi:10.1016/j.cancergenyto.2010.09.006.

[4] Thakker RV. Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4). Mol Cell Endocrinol 2014;386(1–2):2–15 [PMC
free article] [PubMed] [CrossRef] [Google Scholar]. doi:10.1016/j.mce.2013.08.002.

[5] Ito T, Igarashi H, Uehara H, Berna MJ, Jensen RT. Causes of death and prognostic factors in multiple endocrine
neoplasia type 1: a prospective study: comparison of 106 MEN1/Zollinger-Ellison syndrome patients with 1613
texture MEN1 patients with or without pancreatic endocrine tumors. Medicine (Baltimore) 2013;92(3):135–81
[PMC free article] [PubMed] [CrossRef] [Google Scholar]. doi:10.1097/MD.0b013e318295a4f1.

[6] Donegan D, Singh Osypina N, Rodriguez-Gutierrez R, et al. Long-term outcomes in patients with multiple endocrine
neoplasia type 1 and pancreaticoduodenal neuroendocrine tumours. Clin Endocrinol (Oxf) 2017;86(2):199–206 [PubMed]
[CrossRef] [Google Scholar]. doi:10.1111/cen.13264.

[7] Burgess JR, David R, Greenway TM, Parmeswaran V, Shephard JJ. Osteoporosis in Multiple Endocrine Neoplasia
Type 1: severity, clinical significance, relationship to primary hyperparathyroidism, and response to parathyroidectomy.
Arch Surg. 1999;134:1119–23 [PubMed] [CrossRef] [Google Scholar]. doi:10.1001/archsurg.134.10.1119.

[8] Lourencio DM Jr, Coutinho FL, Toledo RA, Montenegro FL, Correia-Deur JE, Toledo SP. Early-onset, progressive, frequent,
extensive, and severe bone mineral and renal complications in multiple endocrine neoplasia type-1 associated primary
hyperparathyroidism. J Bone Miner Res. 2010;25:2382–91 [PubMed] [CrossRef] [Google Scholar].
doi:10.1002/jbmr.125.

[9] Michaud L, Balogova S, Burgess A, et al. Pilot comparison of 18F-fluorocholine PET/CT, ultrasonography and
123I/99mTc-sestaMIBI dual-phase dual-isotope scintigraphy in the preoperative localization of hyperfunctioning
parathyroid glands in primary or secondary hyperparathyroidism: influence of thyroid anomalies. Medicine (Baltimore)
2015;94(41):e1701 [PMC free article] [PubMed] [CrossRef] [Google Scholar].
doi:10.1097/MD.0000000000001701.

[10] Doherty GM, Lairmore TC, DeBenedetti MK. Multiple endocrine neoplasia type 1 parathyroid adenoma
development over time. World J Surg 2004;28(11):1139–42 [PubMed] [CrossRef] [Google Scholar].

[11] Marx SJ, Simonds WF. Hereditary hormone excess: genes, molecular pathways, and syndromes. Endocr Rev.
2005;26:615–61 [PubMed] [CrossRef] [Google Scholar]. doi:10.1210/er.2003-0037.

[12] Singh Osypina N, Donegan D, Rodriguez-Gutierrez R, Al-Hilli Z, Young WF Jr. Assessing for multiple endocrine
neoplasia type 1 in patients evaluated for Zollinger-Ellison syndrome—clues to a safer diagnostic process. Am J Med
[13] Poitras P, Gingras MH, Rehfeld JF. The Zollinger-Ellison syndrome: dangers and consequences of interrupting antisecretory treatment. Clin Gastroenterol Hepatol 2012;10(2):199–202 [PubMed] [CrossRef] [Google Scholar]. doi: 10.1016/j.cgh.2011.08.012.

[14] Triponez F, Dossen D, Goudet P, Cougard P, Bauters C, Murat A, et al. Epidemiology data on 108 MEN 1 patients from the GTE with isolated nonfunctioning tumors of the pancreas. Ann Surg. 2006;243:265–72 [PMC free article] [PubMed] [CrossRef] [Google Scholar]. doi: 10.1097/01.sla.0000197715.96762.68.